Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -9 of 9
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/4/2007
 
First Published:
3/1/1995
1.
Phase III Randomized Study of Total Androgen Blockade With or Without Pelvic Irradiation in Patients With Locally Advanced Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Under 80
NCI
CAN-NCIC-PR3
CALGB-9593, ECOG-JPR03, MRC-PR07, SWOG-JPR3, EU-99013, NCI-T94-0110O, ISRCTN24991896, T94-0110, NCT00002633, PR3
Last Modified:
1/28/2004
2.
Phase III Study of Chemo/Hormonal Therapy vs Androgen Ablation Alone as Initial Therapy in Patients With Unresectable/Metastatic Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
NCI
MDA-DM-95231
NCI-G96-1044, NCT00002855
Last Modified:
2/23/2007
 
First Published:
1/1/1999
3.
Phase III Randomized Study of Intermittent Versus Continuous Androgen Suppression in Patients With Prostate-Specific Antigen Progression in the Clinical Absence of Distant Metastases After Prior Radiotherapy for Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
16 and over
NCI
CAN-NCIC-PR7
SWOG-JPR7, ICR-CTSU-JPR7, JPR7, NCT00003653, PR7
Last Modified:
6/1/1989
4.
Phase III Randomized Double-Blind Trial of Antiandrogen Therapy with Anandron plus the LHRH Agonist Zoladex vs Placebo in Patients with Unresectable Hepatocellular Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
postpubertal
EORTC-40861
Last Modified:
2/1/1988
5.
Phase III Randomized Comparison of Leuprolide/Anandron vs Leuprolide/Placebo in Patients with Stage D2 Carcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
40 to 85
FCCC-86814
NCI-V87-0282
Last Modified:
11/11/2008
 
First Published:
8/1/2000
6.
Phase II Randomized Study of Vaccine Containing Recombinant Vaccinia-Prostate-Specific Antigen (PSA) Admixed With rV-B7.1 Plus Recombinant Fowlpox-PSA Vaccine, Sargramostim (GM-CSF), and Interleukin-2 Versus Nilutamide Alone in Patients With Hormone-Refractory Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
NCI-00-C-0137
MB-NAVY-99-04, NCI-T99-0097, T99-0097, NCT00020254
Last Modified:
6/10/2005
 
First Published:
1/1/2002
7.
Phase II Study of Early Estramustine, Etoposide, and Paclitaxel With Combined Androgen Blockade Therapy in Patients With High-Risk Metastatic Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
Over 18
NCI
SWOG-S0032
S0032, NCT00028769
First Published:
3/24/2004
8.
Phase II Randomized Study of Combined Androgen Ablation With Versus Without Adjuvant Docetaxel and Estramustine in Patients With Androgen-Dependent Recurrent Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
MDA-DM-99224
Last Modified:
1/31/2008
 
First Published:
7/24/2007
9.
Phase I Study of Limited Androgen Ablation and Antiandrogen Therapy Followed by Temsirolimus in Patients With Biochemically Relapsed Prostate Cancer After Prostatectomy and/or Radiotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
Not specified
NCI
MDA-2007-0025
7862, 2007-0025, NCT00512668
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute